Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17478472rdf:typepubmed:Citationlld:pubmed
pubmed-article:17478472lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:17478472lifeskim:mentionsumls-concept:C0003873lld:lifeskim
pubmed-article:17478472lifeskim:mentionsumls-concept:C0920317lld:lifeskim
pubmed-article:17478472lifeskim:mentionsumls-concept:C0021755lld:lifeskim
pubmed-article:17478472lifeskim:mentionsumls-concept:C1456820lld:lifeskim
pubmed-article:17478472lifeskim:mentionsumls-concept:C0456081lld:lifeskim
pubmed-article:17478472lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:17478472lifeskim:mentionsumls-concept:C0439852lld:lifeskim
pubmed-article:17478472lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:17478472pubmed:issue7lld:pubmed
pubmed-article:17478472pubmed:dateCreated2007-6-25lld:pubmed
pubmed-article:17478472pubmed:abstractTextNew treatments that inhibit the cytokines tumour necrosis factor alpha (TNFalpha) and interleukin 1 (IL-1) in the treatment of rheumatoid arthritis have proven clinical effect against placebo and methotrexate (MTX) in several clinical trials in early and late-stage disease and different severity groups. Since there are no head-to-head randomized controlled trials directly comparing the currently available treatments, etanercept, adalimumab, infliximab or anakinra, we perform a meta-analysis that adjusts for differences between study characteristics, and allows indirect comparisons between treatments.lld:pubmed
pubmed-article:17478472pubmed:languageenglld:pubmed
pubmed-article:17478472pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17478472pubmed:citationSubsetAIMlld:pubmed
pubmed-article:17478472pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17478472pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17478472pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17478472pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17478472pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17478472pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17478472pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17478472pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17478472pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17478472pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17478472pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17478472pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17478472pubmed:statusMEDLINElld:pubmed
pubmed-article:17478472pubmed:monthJullld:pubmed
pubmed-article:17478472pubmed:issn1462-0324lld:pubmed
pubmed-article:17478472pubmed:authorpubmed-author:NixonRRlld:pubmed
pubmed-article:17478472pubmed:authorpubmed-author:BrennanAAlld:pubmed
pubmed-article:17478472pubmed:authorpubmed-author:BansbackNNlld:pubmed
pubmed-article:17478472pubmed:issnTypePrintlld:pubmed
pubmed-article:17478472pubmed:volume46lld:pubmed
pubmed-article:17478472pubmed:ownerNLMlld:pubmed
pubmed-article:17478472pubmed:authorsCompleteYlld:pubmed
pubmed-article:17478472pubmed:pagination1140-7lld:pubmed
pubmed-article:17478472pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:17478472pubmed:meshHeadingpubmed-meshheading:17478472...lld:pubmed
pubmed-article:17478472pubmed:meshHeadingpubmed-meshheading:17478472...lld:pubmed
pubmed-article:17478472pubmed:meshHeadingpubmed-meshheading:17478472...lld:pubmed
pubmed-article:17478472pubmed:meshHeadingpubmed-meshheading:17478472...lld:pubmed
pubmed-article:17478472pubmed:meshHeadingpubmed-meshheading:17478472...lld:pubmed
pubmed-article:17478472pubmed:meshHeadingpubmed-meshheading:17478472...lld:pubmed
pubmed-article:17478472pubmed:meshHeadingpubmed-meshheading:17478472...lld:pubmed
pubmed-article:17478472pubmed:meshHeadingpubmed-meshheading:17478472...lld:pubmed
pubmed-article:17478472pubmed:meshHeadingpubmed-meshheading:17478472...lld:pubmed
pubmed-article:17478472pubmed:meshHeadingpubmed-meshheading:17478472...lld:pubmed
pubmed-article:17478472pubmed:meshHeadingpubmed-meshheading:17478472...lld:pubmed
pubmed-article:17478472pubmed:meshHeadingpubmed-meshheading:17478472...lld:pubmed
pubmed-article:17478472pubmed:meshHeadingpubmed-meshheading:17478472...lld:pubmed
pubmed-article:17478472pubmed:meshHeadingpubmed-meshheading:17478472...lld:pubmed
pubmed-article:17478472pubmed:year2007lld:pubmed
pubmed-article:17478472pubmed:articleTitleThe efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons.lld:pubmed
pubmed-article:17478472pubmed:affiliationMRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Robinson Way, Cambridge CB2 2SR, UK. richard.nixon@mrc-bsu.cam.ac.uklld:pubmed
pubmed-article:17478472pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17478472pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:17478472pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:17478472pubmed:publicationTypeMeta-Analysislld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17478472lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17478472lld:pubmed